Craneware Reports Strong H1 FY26 Performance with Double-Digit EBITDA Growth

Craneware H1 FY26 trading update: revenue up 6% and EBITDA growing double‑digit

Craneware’s first half of FY26 looks solid. Revenue rose 6% year‑on‑year to c.$106m, while Adjusted EBITDA increased to approximately $33.4m from $30.3m. Annual Recurring Revenue (ARR) is up about 4% to c.$184.3m, and net revenue retention remains above 100% – a healthy sign that existing customers are sticking around and spending more.

Cash generation remains strong, bank debt is down to $23.4m, and total cash reserves sit at $71.2m after adjusting for $30.3m of cash in transit. Guidance is unchanged: trading is in line with market expectations and management is targeting near‑term double‑digit growth.

Key numbers from Craneware’s H1 FY26

Metric	H1 FY26	H1 FY25
Revenue	c.$106m	$100m
Adjusted EBITDA	c.$33.4m	$30.3m
Annual Recurring Revenue (ARR)	c.$184.3m	$177.3m
Net Revenue Retention	Above 100%	Not disclosed
Total bank debt	$23.4m	$31.6m
Total cash reserves	$71.2m	$72.2m
Cash in transit	$30.3m	Not disclosed

Adjusted EBITDA is a common performance measure that strips out interest, tax, depreciation, amortisation, share‑based payments and acquisition/integration costs to show underlying profitability. On the reported numbers, Craneware’s H1 EBITDA margin looks to be around the low‑30s percentage, which is healthy for a software‑led model.

What is ARR and net revenue retention, and why they matter here

ARR is the annualised value of licence and transaction revenues under contract at period end. It’s a clean way to see the recurring backbone of a software business. Craneware’s ARR grew about 4% to c.$184.3m, a respectable clip given the regulatory noise in the US market.

Net revenue retention (NRR) above 100% means existing customers, in aggregate, increased their spend versus last year after upgrades, cross‑sells and churn. That is typically a hallmark of strong product‑market fit and supports forward visibility.

340B and the HRSA Rebate Model Pilot: short‑term drag, operational proof point

The US Health Resources and Services Administration (HRSA) had launched a Rebate Model Pilot intended to reshape reimbursement within the 340B programme. That pilot has been stayed by a US District Court and HRSA has temporarily halted it. For providers, that brings welcome short‑term clarity; for Craneware, the halt affected reported revenue and ARR growth tied to signed sales contracts in that area.

Two takeaways. First, growth was dented but still positive, which speaks to diversity in the base business. Second, the company’s quick launch of a viable Rebate solution on its Trisus platform is a good operational signal: it shows they can move fast when rules shift. In a market as fluid as US healthcare, that agility matters.

Cash generation, debt and balance sheet strength

Craneware highlights high operating cash conversion, used to invest in product, reduce debt and lower interest costs. Bank debt fell to $23.4m (from $31.6m) and cash reserves total $71.2m after adjusting for $30.3m of cash in transit. Cash in transit refers to receipts that are due but not yet settled onto the balance sheet at period end.

In plain terms, the balance sheet looks robust for a company of this profile: high recurring revenues, solid cash generation and modest net debt. That gives management options – continued investment in Trisus, potential bolt‑on innovation, and resilience if macro conditions wobble.

Operational momentum: Trisus platform and partnerships

Management points to continued innovation and operational efficiency as key drivers. The Trisus cloud ecosystem is central – unifying revenue intelligence, margin intelligence and analytics for US providers. Collaborations with Microsoft and Oracle are flagged as strategic, though no financial terms are disclosed.

The broader message is positioning: Craneware sees itself as an independent data and insights provider embedded in the financial plumbing of US healthcare. With NRR above 100% and ARR growing, customers appear to be increasing usage across the platform and partner offerings.

Guidance and outlook: in line and aiming for double‑digit growth

Full‑year trading is in line with current market expectations for FY26. Management reiterates that the Group is on track to deliver double‑digit growth in the near term, supported by a robust pipeline and favourable market conditions. No changes to guidance numbers were provided.

Positively, recurring revenue and cash generation provide good visibility. The main watch‑item is regulatory churn around programmes like 340B, which already tempered growth within a specific set of signed contracts this half.

The good, the not‑so‑good, and my take

• Positives: Revenue up 6%, Adjusted EBITDA up to c.$33.4m, ARR up to c.$184.3m, NRR above 100%, strong cash conversion, reduced bank debt, and cash reserves of $71.2m.
• Less positive: ARR growth of c.4% and revenue growth were dampened by the HRSA pilot dynamics; precise cash conversion and margin numbers are not disclosed; headline figures are presented as circa where applicable.
• My take: This is a clean, confidence‑building update. Despite a regulatory headwind, Craneware delivered growth, protected customer outcomes with a rapid Rebate solution, and strengthened the balance sheet. It reads like a company executing its plan in a tough macro backdrop.

What to watch next

• H1 results on 2 March 2026 – fuller detail on margins, cash conversion and segmental trends.
• ARR and NRR progression – do we see acceleration as the 340B disruption eases.
• Cash and debt – continued deleveraging and interest cost benefits.
• Trisus adoption – evidence of deeper platform usage and contribution from partner offerings.

Jargon buster

• Adjusted EBITDA: Earnings before interest, tax, depreciation, amortisation, share‑based payments and acquisition/integration costs – a proxy for underlying operating profitability.
• ARR (Annual Recurring Revenue): The annualised value of contracted licence and transaction revenues at period end.
• Net Revenue Retention: How revenue from existing customers changes over a year, including upsells and churn. Above 100% means growth from the installed base.
• Cash in transit: Cash due to the company that has been collected but not yet settled into Craneware’s bank accounts at the period end.
• 340B/HRSA Rebate Model Pilot: A US programme affecting how certain drug discounts and reimbursements work for healthcare providers; the pilot’s halt added short‑term clarity but affected Craneware’s growth tied to related contracts.

Overall, Craneware’s H1 FY26 trading update combines steady top‑line growth, improving profitability and disciplined cash management. With recurring revenue, strong retention and a clear platform strategy, the company looks well set for the remainder of FY26 – with the usual caveat that regulatory change remains the wildcard to monitor.